On September 18, Tempus AI fell 5.04% in regular trading to $76.31 per share, with turnover of approximately $293 million. Notably, the stock had surged as much as 14% intraday before reversing sharply into negative territory.
The reversal was triggered by a Form 144 filing revealing that CEO and Chairman Eric Lefkofsky plans to sell 200,000 shares of Class A common stock through J.P. Morgan Securities LLC on NASDAQ, valued at approximately $13.994 million. This marks the third such filing in recent months, following a 250,000-share disposal in late August and another 249,000-share sale in late July, all executed under a pre-arranged Rule 10b5-1 trading plan.
Despite a string of recent catalysts — including the announcement of the world's largest multimodal whole-genome dataset, FDA clearance for its AI-enabled pulmonary hypertension detector, up to $9.5 million in ARPA-H funding for a cardiology AI agent, and Q2 results that beat estimates on both revenue ($382.5M vs. $379.7M est.) and adjusted EPS (-$0.04 vs. -$0.14 est.) — repeated insider selling amid a rapid four-session rally of over 36% intensified profit-taking pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments